Table 1 Demographic and clinical characteristics of enrolled PWE.
Demographic and clinical characteristics | Drug-free (n = 13) | On VA therapy | |
|---|---|---|---|
VA Responders (n = 15) | VA Non-responders (n = 8) | ||
Male: Female ratio | 7/6 | 9/6 | 4/4 |
Age, median (IQR), years | 18.0 (14.0–23.0) | 23.0 (19.5–26.0) | 20.0 (17.0–28.0) |
Age at onset, median (IQR), years | 14.0 (13.0–18.0) | 13.0 (12.0–16.0) | 13.0 (7.0–17.0) |
BMI, median (IQR), kg/m2 | 16.9 (15.8–19.4) | 21.9 (19.1–25.4) | 19.2 (18.0–22.1) |
Treatment duration, median (IQR), months | — | 22.0 (16.0–29.8) | 20.5 (16.0–26.3) |
Maintenance dose [mg/day] | |||
median (IQR) | — | 800 (400–1000) | 800 (800–1050) |
Dosage [(mg/day)/kg] | |||
median (IQR) | — | 16.3 (11.4–17.5) | 16.7 (15.8–20.4) |
Serum drug level [mg/L] | |||
median (IQR) | — | 83.7 (76.1–103.4) | (72.2–96.2) |
Dose corrected serum drug level [(mg/L)/[(mg/day)/kg]] | |||
median (IQR) | — | 5.3 (4.9–10.1) | 5.3 (4.6–6.5) |
